Protara Therapeutics, Inc. (TARA:NASDAQ) closed at $2.53 on November 13, 2026, up 3.69% on the day. The stock trades 67.6% below its 52-week high of $7.82 and 21.1% above its 52-week low of $2.09. Over the past year, it lost 54.1%. Protara Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, TARA closed higher on 116 days (46%). Its best day was November 18, 2025 (+21.18%) and its worst was February 24, 2026 (-26.38%). The stock moved 10% or more in a single session 7 times.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Find more stocks like TARA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.